← Back to Screener
Clearmind Medicine Inc. Common Shares (CMND)
Price$3.17
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-111.43%
Price vs S&P 500 (4W)-50.56%
VGM Score18.25
Market Capitalization$3.65M
All Metrics
Book Value / Share (Quarterly)$79.23
P/TBV (Annual)1.88x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-351.57
Price vs S&P 500 (YTD)-91.15%
EPS (TTM)$-483.16
10-Day Avg Trading Volume5.33M
EPS Excl Extra (TTM)$-483.16
EPS (Annual)$-303.46
ROI (Annual)-166.25%
Cash / Share (Quarterly)$259.96
ROA (Last FY)-72.42%
EBITD / Share (TTM)$-189.26
ROE (5Y Avg)-249.70%
Cash Flow / Share (Annual)$-455.78
P/B Ratio3.42x
P/B Ratio (Quarterly)5.05x
Net Interest Coverage (TTM)-2.74x
ROA (TTM)-70.45%
EPS Incl Extra (Annual)$-303.46
Current Ratio (Annual)1.72x
Quick Ratio (Quarterly)1.28x
3-Month Avg Trading Volume0.93M
52-Week Price Return-99.07%
Tangible BV / Share (Quarterly)$71.79
52-Week High$524.00
EPS Excl Extra (Annual)$-303.46
26-Week Price Return-95.50%
Quick Ratio (Annual)1.71x
13-Week Price Return-68.87%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)1.32x
Enterprise Value$181,200
Cash / Share (Annual)$643.83
3-Month Return Std Dev236.36%
ROE (Last FY)-169.09%
Net Interest Coverage (Annual)-19.64x
EPS Basic Excl Extra (Annual)$-303.46
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-483.16
Receivables Turnover (Annual)0.00x
ROI (TTM)-170.64%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$281.35
Price vs S&P 500 (52W)-127.28%
Year-to-Date Return-80.22%
5-Day Price Return58.41%
EPS Normalized (Annual)$-303.46
ROA (5Y Avg)-233.83%
Month-to-Date Return-49.72%
EBITD / Share (Annual)$-442.86
ROI (5Y Avg)-249.14%
EPS Basic Excl Extra (TTM)$-483.16
P/TBV (Quarterly)5.57x
P/B Ratio (Annual)1.81x
Book Value / Share (Annual)$291.51
Price vs S&P 500 (13W)-78.62%
Beta19.87x
Revenue / Share (TTM)$0.00
ROE (TTM)-173.63%
52-Week Low$2.10
mGradeF
vgmGradeF
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CMNDClearmind Medicine Inc. Common Shares | — | — | F | $3.17 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Clearmind Medicine is a clinical-stage biopharmaceutical company developing MEAI, a novel psychedelic compound, for treating mental health disorders including alcohol use disorder, binge drinking, and eating disorders. The company is advancing its lead candidate through Phase I/IIa clinical trials with operations based in Israel.